Moving from accelerated burden reduction to malaria elimination in Zambia
TB policies in 29 Countries
A survey of prevention, testing and treatment policies and practices
Trials (2017) 18:152, DOI 10.1186/s13063-017-1881-z
The study is based on in-depth, semi-structured qualitative interviews with 60 Syrians who arrived in Spain between 2015 and 2017.
There are social and environmental barriers faced by persons with disabilities which have been reported in literature. In discussing these barriers, attention is yet to be given to the support from families to members with disabilities. This study aimed to examine family support and its impact on th...e lives of persons with disabilities in Ghana.
more
Октябрь 2017
Русский
Рекомендации EACS 9.0
Technical Update
HIV Treatment
July 2017
Original Research
African Journal of Primary Health Care & Family Medicine
ISSN: (Online) 2071-2936, (Print) 2071-2928
Open Access
Report: A survey conducted among the 27 high MDR-TB burden countries.
March – July 2015
Stop TB Partnership in collaboration with Medecins Sans Frontieres (MSF).
Accessed November 2017.
UNAIDS 2017 / Reference
Generating evidence for policy and action on HIV and social protection
Application of a One Health approach .
The present guidance was developed with the support of the WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) to assist countries and other stakeholders in the establishment and development of programmes of integrated surveillan...ce of antimicrobial resistance in the foodborne bacteria (i.e., bacteria commonly transmitted by food) by taking a One Health approach.
more
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more
National Tuberculosis and Leprosy Control Program